Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...
Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...
About 6% of Leqembi (lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the drug’s single-use vials. This waste costs Medicare about $1,600 a patient ...
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback